

Fanvestments Corporation
Global Investments - Global Returns
Invest today, Build Wealth Forever

FVAM Fund Quarterly Portfolio Report
Q4 - 2023

Fanvestments Private Diversified Alternative Investment Fund (FVAM)

This Report describes the Fanvestments Private Alternative Investment Fund (the "Fund", "FVAM"). Fanvestments Corporation (the "Management"), a Rhode Island S-Corporation, serves as the Fund's Management Business. The following summary highlights information about the fund, during and as of the 4th Quarter of 2023, and info about the fund's investment strategy and expectations. Except where the context otherwise requires or indicates, in this report, (i) "Fanvestments," "the Business," "we," "us", "Firm", "management" and "our" refer to Fanvestments Corporation and/or owner, and its Primary offering, with respect to FVAM, a Private Alternative Investment Fund, referred to as "the Fund", "the portfolio", or "FVAM".

Contact and Social Media:

Fanvestments, Corporation

Matthew Fanning – Owner / Founder / CIO / Fund Manager

mfanning@fanvestments.com

www.fanvestments.com

Twitter: @fanvestments

facebook.com/fanvestments

Instagram: @fanvestments

PRINCIPAL INVESTMENT STRATEGY

The FVAM Fund consists of a diversified portfolio primarily focused on investing long within individual stocks & ETF's, "Equity long-bias", as well as occasional exposure between commodities, fixed income and currencies. FVAM has a dual goal of capital appreciation AND preservation, looking for strong returns while applying a layer of defense to handle all types of economic and global financial cycles and market volatility. The fund applies multiple strategies, from fundamental research looking at earnings, revenue, growth rates, and valuation, to analyzing historical data and projecting future expectations. Combining fundamentals with technical analysis ("technical"), studying charts and price action for trends, as well as trend change, price and timeframe analysis, overbought and oversold indicators, and volume spikes leading to capitulation. The macro environment is very important as well, and will overlay macro research on top of other research and overall portfolio analysis. Other strategies, more of a focus within a sector, such as biotech, looking for companies that are trying to find a cure for major diseases. Within Technology, to find innovation helping to disrupt and shape the future, such as AI, Big Data, Cloud, Analytics, FinTech (financial technology). As well as to find the Founders that are all-in and have a sense of brilliance. Price and Returns tend to trump timeframes, "PriceFrame", being a far more important metric than timeframe, but the fund does expect to hold most core investments for multiple years, mid-to-long term.

The Fund is actively-managed with a blended investment style, looking for Growth at a great Value, Growth-on-Sale (GOS), utilizing more of a "buy the blood" strategy, buy low-sell high, as a fundamental mindset. The fund will also seek to find opportunities within event-driven strategies, such as potential buy-outs/mergers, FDA approvals, momentum and fund flows, as well as unusual options action. Part of the investment style is to bring together a diversified multi-asset "401k retirement" portfolio approach, combined with hedge fund, institutional style investment involving individual stock picking alongside minimal hedging against general market risk, as well as having low market correlation producing independent fund-specific returns. Only on a limited basis, and kept to very small exposure at most times, the fund does use multiple hedging strategies to protect from general stock market volatility, as well as downside risk within individual positions, or macro issues such as economic cycles, recessions, geopolitics. In most hedge or short exposure cases, the fund will utilize options strategies for short exposure vs outright selling short, such as index/ETF options, VIX (volatility) options, positional hedges. Overall hedging exposure is kept low, utilizing more of a hedge by allocation strategy, such as Diversification and Position sizing, asset allocation management, and always monitoring positional exposure relative to the risk of that position and overall portfolio size. As well as other portfolio management strategies such as performance monitoring and risk management, constantly studying fund volatility and day-to-day performance statistics.

The FVAM fund, is designed to be an all-weather style fund, "all-markets", meaning the fund can navigate through all types of economic and market cycles, taking advantage of the upside and withstanding periods of major market selloffs. FVAM is not a "thematic" fund, and its diversified, risk-sensitive strategies are built to suit investors of all-ages, from younger and just starting to invest, through all stages of retirement and life. From the start, the fund always had intention to relate to the "conservative" retiree investor, where this group, at least to me, seems to give up an extreme amount of capital growth in the years where it's needed most. FVAM is built to be worthy of a large portion of an overall portfolio, to pair perfectly alongside something like a 60-40 style strategy, and is built to be a forever investment. Since FVAM is not intending to mirror, or match the assets or performance of any other index or ETF, the fund's performance will not have any intention to directly match the performance of any other investment vehicle, ETF, or Index or have the same timing as the overall markets. FVAM's intent is to have created its own unique investment vehicle, with individual assets selected by Fanvestments Management, minimal market correlation, and less volatility vs market indices. Although compared to the S&P 500, this is not the fund's true benchmark, as the index is strictly a US large-cap index. FVAM is diversified among multiple market caps and sectors, multiple strategies, and has international exposure. Utilizing a dynamic and perpetually improving investment strategy combining increased Portfolio Quality, constant Portfolio analysis, non-stop financial market study, risk and allocation management, along with relentless analysis of performance metrics, statistics, with the goal of perpetual improvement. Matching up technical analysis for timing with Fundamental analysis for valuation, and overlaying Macro environment research to help find Global trends and determine overall Market risk.

Make the Money Make More Money.

Q4 Highlights

For the 4th Quarter of 2023, the FVAM fund finished up, with a positive +7.3% return. FVAM had a down October, but strong back-to-back months in November/December. The fund was down -2.9% in October, up 5.3% in November, and up 4.9% in December. On a relative basis for the year thru the 4th Quarter, based on an internal performance tracker of ~40 indexes/sectors, FVAM was outperforming just about half of the components. For the 4th Quarter, the S&P 500 was up 10.8%, the Dow Jones up 11.9%, with the small cap etf IWM, up 13.4%. The ACWX etf, which tracks stocks around the world excluding the United States, was up 8.5%, w/the RSP (equal-weight SP500) up 11%. Cathie Wood's ARKK thematic growth & innovation fund, was up 30%. Although there is no attempt to match the performance or timing of the S&P 500, along with mixed-asset exposure, multi-cap and multi-strategy, lower risk & volatility, and with equity exposure around 80-85% of the fund, the fund's performance and volatility is analyzed against the index, an all-stock and strictly large-cap index. Other reference points, more relative and important benchmarks for the fund, are Warren Buffett's Berkshire Hathaway, as well as SPLV, which is the S&P 500 Low Volatility etf. A less volatile alternative to the SP500 is a major goal/focus of the FVAM fund, making the SPLV a top benchmark for the fund. Using the BRK/b shares, Berkshire was up 2% for the 4th quarter, w/SPLV was up 6.5%, FVAM outperforming both. For 2023, BRKb was up 15.5%, with the SPLV ending the year down 2%. FVAM finished 2023 up 11.2%, slightly underperforming Berkshire, but huge outperformance vs SPLV.


The fund's top performing investments for 2023 were Tesla (TSLA), Amazon (AMZN), Grayscale Ethereum (ETHE) as the top three. Following them up was Charles Schwab (SCHW), Crisper Therapeutics (CRSP), Live Nation (LYV), Google (GOOGL), Target (TGT), Hive Digital (HIVE) and Boeing (BA) rounding out the top 10 performing positions. Of those top 10; SCHW, LYV, GOOGL, and BA have been mostly sold by early Q1-2024, all for gains. SCHW was the 4th best performer for the fund in '23, LYV 6th best, GOOGL 7th best, with BA at #11. Positions in Tesla, Amazon, Ether, Crispr, Target and Hive remain. Tesla, which was the fund's top performer in '23, has been reduced (closer to a 1-2% position), and started buying back late in Q1-2024. Amazon is currently the fund's largest position. ETHE, CRSP remain around 2-4% positions, w/Hive reduced to a smaller non-core options position. In the quarter, Alibaba (BABA), Nike (NKE), MP Materials (MP), Albermarle (ALB), Renaissance IPO (IPO) were sold-in-full, and reduced positions in Coupang (CPNG). Fund bought back into Netflix (NFLX), added to Disney (DIS), and initiated new core positions in Target (TGT) and Novo Nordisk (NVO). Looking further into Novo Nordisk, currently a top 10 position for the fund in size (as of late Q1 '24), with the stock up ~25% towards late Q1, and remains a longer-term "core" investment. NVO, a global healthcare co., a major player in the GLP-1 space for diabetes and weight mgmt, maker of ozempic, and also involved in rare diseases such as cardiovascular and Alzheimer's. Novo has about 1/3 of the global branded diabetes market share. Position was initiated just under \$100/share w/avg price ~101. Stock hit above \$138 in early March '24. Expectations are for 30% sales growth, where the current 3yr sales growth avg is @ 22%, expecting eps growth of ~25%+. Based on those growth rates would get '24 revenue to \$44 billion, and eps ~3.50/share. 12-18 month price target at \$220, another 70%+ upside from current levels. Looking at multiple variables, but comes to about a PEG of 2.5 (or a PE ~60), or 17x '25 Sales. Can read more about NVO here: [Novo Nordisk Investor presentation](#)

Looking into Q1 2024, new positions were initiated in Advanced Auto Parts (AAP), Devon Energy (DVN), Indie Semiconductor (INDI), China Internet etf (KWEB), iShares Russell 2000 etf (IWM), and the Spdr Biotech etf (XBI). Fund added to Novo Nordisk (NVO), Amazon (AMZN), Netflix (NFLX), and Tesla (TSLA). Positions in JD.com, Boeing (BA) and Schwab were sold in full, Schwab a top performer in '23, and back on the watch list. The fund has taken a smaller options position in Bank of America (BAC). Amazon, IWM, and XBI have become the top 3 positions in size. Regarding IWM and XBI, both have a similar core strategy, as the entire fund currently has macro tilt towards "rates have peaked" for this cycle. This is a major tailwind for small caps, which the IWM represents, as well as Biotech, which many need lower rates to survive. To put weight into this thesis without crazy volatility, went with the baskets. For AMZN, belief is Amazon will continue to be a long-term secular winner, as the world turns to amazon more & more for more & more. The fund started buying AMZN in late January '23 around \$105 and has an average cost just above \$120, with the stock just above \$180 in late-March '24. AMZN is a top performer so far in 2024. Expecting sales growth of 15% with EPS growth of 25%, would get '24 revenue to 662 Billion, and '24 eps @ \$3.77. Using multiple metrics but averaging to 4x '24 sales or a 2.5 PEG, 12-month price target @ 270, ~50% upside. Longer-term, could see Amazon get to a \$5 Trillion market cap, currently @ 1.8t, close to a triple off current levels.



Can read more about Amazon here: [AMZN Q4-2023 Results](#)

Below shows reporting created & analyzed within Data Analytics software, Tableau Software, which has data integration into the fund's internal database/spreadsheets. (*Portfolio Data as of October 2023)

High Level allocation heat map and pie chart:




Below shows the further breakdown of only the fund's individual stock exposure.




Performance Analysis: Analyzing the breakdown of the Fund's performance, as well as comparisons to other investment vehicles/index, such as the S&P 500, \$BRK-b (Warren Buffett's 'Berkshire Hathaway'), ACWX which tracks Global Markets minus the US (World x-US), and the Russell 2000 small cap index (\$IWM)


FVAM fund, 4th Quarter 2023




FVAM fund, 2023 YTD cumulative return




FVAM fund (green) vs SPX (S&P 500, orange), Q4 2023, weekly




FVAM fund (green) vs SPLV (S&P 500 low-volatility, orange), 1-year, weekly




FVAM fund (green, left) vs BRK/b (blue, right), 1-year (thru November '23), Weekly (\$BRK-B : Berkshire Hathaway B-shares)




FVAM fund (green, left) vs BRK/b (blue, right), Q4 2023, Weekly




FVAM vs BRK/b and relative return (FVAM vs BRK/b), weekly, 2023
 (excess: positive = outperformance, negative = underperformance)




FVAM vs BRK/b and relative return (FVAM vs BRK/b), Q4 2023
 (excess, positive = outperformance, negative = underperformance)




FVAM (Green) vs S&P500 vs IBB (BioTech Index Fund) vs BRK/b (Berkshire Hathaway) , 4th Quarter - 2023




FVAM (green) vs S&P500 vs BRK/b (Berkshire Hathaway) vs ACWI (World Index) vs IBB (BioTech Index Fund) vs LQD (Bonds) vs EEM (Emerging Markets) vs QQQ (Nasdaq), Q4 '23




FVAM vs SPX and relative return (FVAM vs SPX), Q4 - 2023, weekly
 (*excess return shows relative performance)




FVAM vs SPX and relative return (FVAM vs SPX), full year 2023




FVAM vs IWM (small caps) vs IBB (biotech) vs SPX (S&P 500) vs ACWI (world index) vs ACWX (world x-US) vs LQD (bonds), Weekly, Q4




FVAM vs S&P 500 (\$SPX) vs Berkshire Hathaway (\$BRK/b) vs \$SPLV (S&P500 Low Volatility etf) vs \$ACWX (World Index x-US etf), Weekly, Q4




FVAM (green) vs EEM (Emerging Markets) , full year '23




FVAM (green) vs LQD (Investment Grade Corporate Bonds), full year '23, Monthly




S&P 500 vs ACWX (blue, World Index minus U.S.), Q4 2023, Weekly



FVAM vs ACWI (World Index), with Relative Return (excess return), Q4 2023




FVAM (green) vs ACWX (World Index minus USA, blue) vs S&P 500, Full year '23 thru Feb '24, monthly returns



Reference 1: FVAM Fund Performance Stats (showing view of December 2023, FVAM vs SPX, Statistics)

The data below, displaying just December 2023 in this example, shows performance statistic data maintained daily, showing the FVAM fund vs the S&P 500, even though FVAM is not trying to match or mimic the actual underlying stocks, within the S&P 500, or match the performance of the index. Data shows performance for FVAM, performance for the S&P 500 (\$SPX), as well as relative performance and mathematical statistics (showing risk & volatility). The chart displays daily performance for both FVAM (green) and SPX (blue). Another very important factor for FVAM is to be less volatile than the SPX, which is being analyzed using Statistics, such as Standard Deviation (SDDEV). Excess Return shows relative performance between FVAM and \$SPX (outperformance positive, or underperformance negative). Index C shows plus or minus on a progressive (rolling) basis through the month. The "match (golf)" column also shows that progressive relative performance, but for larger outperformance or underperformance, using a 50bp (+/- 0.5%) differential.

December 2023



*SPX (S&P500 index), BRK/B (Berkshire Hathaway) and any other index/fund/investment vehicles' performance using internal data tracking and data from multiple public internet sources, "non-official" data only.

Heat Map for the Nasdaq 100 Index, showing each stock within that index/sector along with its relative size and weight compared to the overall index (**larger the block size the larger percentage that stock makes up within the index**) (*as of early March 2023)



